bALP and OC levels before and after treatment with bortezomib or alternative therapy
| . | Bortezomib . | Control group . | ||
|---|---|---|---|---|
| Mean ± SD . | P . | Mean ± SD . | P . | |
| bALP, U/L | <.001 | NS | ||
| Before treatment | 19.7 ± 19.8 | 24.8 ± 21.5 | ||
| After treatment | 30.2 ± 29.5 | 23.3 ± 23.7 | ||
| Osteocalcin, μg/L | .024 | NS | ||
| Before treatment | 6.3 ± 13.6 | 6.97 ± 7.7 | ||
| After treatment | 10.8 ± 21.5 | 6.6 ± 9.5 | ||
| bALP, U/L | ||||
| Responders, n=14 | .004 | — | ||
| Before bortezomib | 22.0 ± 26.2 | — | ||
| After bortezomib | 35.3 ± 36.5 | — | ||
| Nonresponders, n=11 | .016 | — | ||
| Before bortezomib | 16.7 ± 5.8 | — | ||
| After bortezomib | 23.6 ± 16.5 | — | ||
| Bortezomib monotherapy, n=13 | .004 | — | ||
| Before bortezomib | 22.2 ± 27.3 | — | ||
| After bortezomib | 33.2 ± 38.3 | — | ||
| Bortezomib/dexamethasone, n=12 | .021 | — | ||
| Before bortezomib | 17.0 ± 5.4 | — | ||
| After bortezomib | 26.9 ± 16.5 | — | ||
| . | Bortezomib . | Control group . | ||
|---|---|---|---|---|
| Mean ± SD . | P . | Mean ± SD . | P . | |
| bALP, U/L | <.001 | NS | ||
| Before treatment | 19.7 ± 19.8 | 24.8 ± 21.5 | ||
| After treatment | 30.2 ± 29.5 | 23.3 ± 23.7 | ||
| Osteocalcin, μg/L | .024 | NS | ||
| Before treatment | 6.3 ± 13.6 | 6.97 ± 7.7 | ||
| After treatment | 10.8 ± 21.5 | 6.6 ± 9.5 | ||
| bALP, U/L | ||||
| Responders, n=14 | .004 | — | ||
| Before bortezomib | 22.0 ± 26.2 | — | ||
| After bortezomib | 35.3 ± 36.5 | — | ||
| Nonresponders, n=11 | .016 | — | ||
| Before bortezomib | 16.7 ± 5.8 | — | ||
| After bortezomib | 23.6 ± 16.5 | — | ||
| Bortezomib monotherapy, n=13 | .004 | — | ||
| Before bortezomib | 22.2 ± 27.3 | — | ||
| After bortezomib | 33.2 ± 38.3 | — | ||
| Bortezomib/dexamethasone, n=12 | .021 | — | ||
| Before bortezomib | 17.0 ± 5.4 | — | ||
| After bortezomib | 26.9 ± 16.5 | — | ||
Adapted from Heider et al68 with permission.
NS indicates not significant; —, not applicable.